1. Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose.
- Author
-
Sorigue, Marc, Sancho, Juan-Manuel, Morgades, Mireia, Moreno, Miriam, Grífols, Juan-Ramon, Alonso, Eva, Juncà, Jordi, Ferrà, Christelle, Batlle, Montserrat, Vives, Susana, Motlló, Cristina, García-Caro, Montserrat, Navarro, Jose-Tomás, Millà, Fuensanta, Feliu, Evarist, and Ribera, Josep-María
- Subjects
DISEASE relapse ,STEM cell transplantation ,HEMATOPOIETIC stem cell transplantation ,HEMATOPOIETIC system ,HEALTH of patients ,DISEASES - Abstract
It is unclear whether higher CD34 + cell doses infused for ASCT have any influence on survival or relapse in patients with lymphoma. We analyzed the correlation of infused CD34 + cell dose with relapse, survival, and hematopoietic recovery in 146 consecutive patients undergoing ASCT for lymphoma. Higher doses (>5 × 106/kg) were significantly correlated with earlier hematopoietic recovery, fewer infectious episodes, lower transfusion needs. No differences were observed in lymphoma outcomes (4-year relapse incidence of 38% [95%CI: 29%–48%] in the lower dose group versus 51% [95%CI: 30%–69%] in the higher dose group, 10-year OS probabilities of 58% [95%CI: 48%–68%] versus 75% [95%CI: 59%–91%], 10-year DFS probabilities of 47% [95%CI: 37%–57%] versus 42% [95%CI: 23%–61%],p = NS for all outcomes). In this series, a higher infused CD34 + cell dose did not correlate with survival or relapse but correlated with earlier hematopoietic recovery and lower resource consumption. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF